Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Deferred Taxes (2023 - 2025)

Protalix BioTherapeutics has reported Deferred Taxes over the past 3 years, most recently at $163000.0 for Q4 2025.

  • Quarterly results put Deferred Taxes at $163000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $340000.0 (up 44.07% YoY), and the annual figure for FY2025 was $340000.0, up 44.07%.
  • Deferred Taxes for Q4 2025 was $163000.0 at Protalix BioTherapeutics, up from $59000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for PLX hit a ceiling of $443000.0 in Q3 2024 and a floor of -$3.1 million in Q2 2023.
  • Median Deferred Taxes over the past 3 years was $38000.0 (2023), compared with a mean of -$279555.6.
  • Biggest five-year swings in Deferred Taxes: skyrocketed 1065.79% in 2024 and later crashed 86.68% in 2025.
  • Protalix BioTherapeutics' Deferred Taxes stood at $38000.0 in 2023, then skyrocketed by 1065.79% to $443000.0 in 2024, then tumbled by 63.21% to $163000.0 in 2025.
  • The last three reported values for Deferred Taxes were $163000.0 (Q4 2025), $59000.0 (Q3 2025), and $231000.0 (Q2 2025) per Business Quant data.